APO Research
Talk to an analyst

APO RESEARCH · REPORT

AI-based Diabetic Eye Disease Screening System

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global AI-based Diabetic Eye Disease Screening System Market Outlook and Growth Opportunities 2026

12 August 2026193 pages

Choose your research edition.

Industry ResearchAI-based Diabetic Eye Disease Screening System Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal AI-based Diabetic Eye Disease Screening System Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal AI-based Diabetic Eye Disease Screening System Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal AI-based Diabetic Eye Disease Screening System Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal AI-based Diabetic Eye Disease Screening System Market Analysis and Forecast 2026-2032171 pages · $4,950 USD

Market perspective

The global AI-based Diabetic Eye Disease Screening System market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for AI-based Diabetic Eye Disease Screening System is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for AI-based Diabetic Eye Disease Screening System is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for AI-based Diabetic Eye Disease Screening System is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the AI-based Diabetic Eye Disease Screening System market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the AI-based Diabetic Eye Disease Screening System market include Remidio, Retmarker, VoxelCloud, Airdoc, Zhiyuan Huitu, IDx, LLC, Zhenhealth, Eyenuk and AEYE Health, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global AI-based Diabetic Eye Disease Screening System market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of AI-based Diabetic Eye Disease Screening System and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents AI-based Diabetic Eye Disease Screening System revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global AI-based Diabetic Eye Disease Screening System market.

AI-based Diabetic Eye Disease Screening System Segment by Company

Remidio

Retmarker

VoxelCloud

Airdoc

Zhiyuan Huitu

IDx, LLC

Zhenhealth

Eyenuk

AEYE Health

Optomed

AI-based Diabetic Eye Disease Screening System Segment by Type

On-premise

Cloud-based

Hybrid Mode

AI-based Diabetic Eye Disease Screening System Segment by Application

General Hospitals

Ophthalmology Hospitals

Diabetes Specialty Hospitals

AI-based Diabetic Eye Disease Screening System Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global AI-based Diabetic Eye Disease Screening System status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the AI-based Diabetic Eye Disease Screening System key companies, revenue, market share, and recent developments.

3. To split the AI-based Diabetic Eye Disease Screening System breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions AI-based Diabetic Eye Disease Screening System market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify AI-based Diabetic Eye Disease Screening System significant trends, drivers, influence factors in global and regions.

6. To analyze AI-based Diabetic Eye Disease Screening System competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI-based Diabetic Eye Disease Screening System market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of AI-based Diabetic Eye Disease Screening System and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI-based Diabetic Eye Disease Screening System.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global AI-based Diabetic Eye Disease Screening System industry.

Chapter 3: Detailed analysis of AI-based Diabetic Eye Disease Screening System company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of AI-based Diabetic Eye Disease Screening System in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of AI-based Diabetic Eye Disease Screening System in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. AI-based Diabetic Eye Disease Screening System Industry Trends Table 2. AI-based Diabetic Eye Disease Screening System Industry Drivers Table 3. AI-based Diabetic Eye Disease Screening System Industry Opportunities and Challenges Table 4. AI-based Diabetic Eye Disease Screening System Industry Restraints Table 5. Global AI-based Diabetic Eye Disease Screening System Revenue by Company (US$ Million) & (2021-2026) Table 6. Global AI-based Diabetic Eye Disease Screening System Revenue Share by Company (2021-2026) Table 7. Global AI-based Diabetic Eye Disease Screening System Company Ranking, (2024-2026) & (US$ Million) Table 8. Global AI-based Diabetic Eye Disease Screening System Key Company Manufacturing Base & Headquarters Table 9. Global AI-based Diabetic Eye Disease Screening System Company, Product Type & Application Table 10. Global AI-based Diabetic Eye Disease Screening System Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global AI-based Diabetic Eye Disease Screening System by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of On-premise Table 15. Significant Companies of Cloud-based Table 16. Significant Companies of Hybrid Mode Table 17. Global AI-based Diabetic Eye Disease Screening System Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global AI-based Diabetic Eye Disease Screening System Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global AI-based Diabetic Eye Disease Screening System Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global AI-based Diabetic Eye Disease Screening System Sales Value Share by Type (2021-2026) Table 21. Global AI-based Diabetic Eye Disease Screening System Sales Value Share by Type (2027-2032) Table 22. Significant Companies of General Hospitals Table 23. Significant Companies of Ophthalmology Hospitals Table 24. Significant Companies of Diabetes Specialty Hospitals Table 25. Global AI-based Diabetic Eye Disease Screening System Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global AI-based Diabetic Eye Disease Screening System Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global AI-based Diabetic Eye Disease Screening System Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global AI-based Diabetic Eye Disease Screening System Sales Value Share by Application (2021-2026) Table 29. Global AI-based Diabetic Eye Disease Screening System Sales Value Share by Application (2027-2032) Table 30. Global AI-based Diabetic Eye Disease Screening System Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global AI-based Diabetic Eye Disease Screening System Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global AI-based Diabetic Eye Disease Screening System Sales Value Share by Region (2021-2026) Table 33. Global AI-based Diabetic Eye Disease Screening System Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global AI-based Diabetic Eye Disease Screening System Sales Value Share by Region (2027-2032) Table 35. Global AI-based Diabetic Eye Disease Screening System Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global AI-based Diabetic Eye Disease Screening System Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global AI-based Diabetic Eye Disease Screening System Sales Value Market Share by Country (2021-2026) Table 38. Global AI-based Diabetic Eye Disease Screening System Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global AI-based Diabetic Eye Disease Screening System Sales Value Market Share by Country (2027-2032) Table 40. Remidio Company Information Table 41. Remidio Business Overview Table 42. Remidio AI-based Diabetic Eye Disease Screening System Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Remidio AI-based Diabetic Eye Disease Screening System Product Portfolio Table 44. Remidio Recent Development Table 45. Retmarker Company Information Table 46. Retmarker Business Overview Table 47. Retmarker AI-based Diabetic Eye Disease Screening System Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Retmarker AI-based Diabetic Eye Disease Screening System Product Portfolio Table 49. Retmarker Recent Development Table 50. VoxelCloud Company Information Table 51. VoxelCloud Business Overview Table 52. VoxelCloud AI-based Diabetic Eye Disease Screening System Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. VoxelCloud AI-based Diabetic Eye Disease Screening System Product Portfolio Table 54. VoxelCloud Recent Development Table 55. Airdoc Company Information Table 56. Airdoc Business Overview Table 57. Airdoc AI-based Diabetic Eye Disease Screening System Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Airdoc AI-based Diabetic Eye Disease Screening System Product Portfolio Table 59. Airdoc Recent Development Table 60. Zhiyuan Huitu Company Information Table 61. Zhiyuan Huitu Business Overview Table 62. Zhiyuan Huitu AI-based Diabetic Eye Disease Screening System Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Zhiyuan Huitu AI-based Diabetic Eye Disease Screening System Product Portfolio Table 64. Zhiyuan Huitu Recent Development Table 65. IDx, LLC Company Information Table 66. IDx, LLC Business Overview Table 67. IDx, LLC AI-based Diabetic Eye Disease Screening System Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. IDx, LLC AI-based Diabetic Eye Disease Screening System Product Portfolio Table 69. IDx, LLC Recent Development Table 70. Zhenhealth Company Information Table 71. Zhenhealth Business Overview Table 72. Zhenhealth AI-based Diabetic Eye Disease Screening System Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Zhenhealth AI-based Diabetic Eye Disease Screening System Product Portfolio Table 74. Zhenhealth Recent Development Table 75. Eyenuk Company Information Table 76. Eyenuk Business Overview Table 77. Eyenuk AI-based Diabetic Eye Disease Screening System Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Eyenuk AI-based Diabetic Eye Disease Screening System Product Portfolio Table 79. Eyenuk Recent Development Table 80. AEYE Health Company Information Table 81. AEYE Health Business Overview Table 82. AEYE Health AI-based Diabetic Eye Disease Screening System Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. AEYE Health AI-based Diabetic Eye Disease Screening System Product Portfolio Table 84. AEYE Health Recent Development Table 85. Optomed Company Information Table 86. Optomed Business Overview Table 87. Optomed AI-based Diabetic Eye Disease Screening System Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Optomed AI-based Diabetic Eye Disease Screening System Product Portfolio Table 89. Optomed Recent Development Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. AI-based Diabetic Eye Disease Screening System Product Image Figure 2. Global AI-based Diabetic Eye Disease Screening System Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global AI-based Diabetic Eye Disease Screening System Market Size (2021-2032) & (US$ Million) Figure 4. Global AI-based Diabetic Eye Disease Screening System Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. On-premise Image Figure 8. Cloud-based Image Figure 9. Hybrid Mode Image Figure 10. Global AI-based Diabetic Eye Disease Screening System Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global AI-based Diabetic Eye Disease Screening System Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global AI-based Diabetic Eye Disease Screening System Sales Value Share by Type (2021-2032) Figure 13. General Hospitals Image Figure 14. Ophthalmology Hospitals Image Figure 15. Diabetes Specialty Hospitals Image Figure 16. Global AI-based Diabetic Eye Disease Screening System Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global AI-based Diabetic Eye Disease Screening System Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global AI-based Diabetic Eye Disease Screening System Sales Value Share by Application (2021-2032) Figure 19. Global AI-based Diabetic Eye Disease Screening System Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global AI-based Diabetic Eye Disease Screening System Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America AI-based Diabetic Eye Disease Screening System Sales Value (2021-2032) & (US$ Million) Figure 22. North America AI-based Diabetic Eye Disease Screening System Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe AI-based Diabetic Eye Disease Screening System Sales Value (2021-2032) & (US$ Million) Figure 24. Europe AI-based Diabetic Eye Disease Screening System Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific AI-based Diabetic Eye Disease Screening System Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific AI-based Diabetic Eye Disease Screening System Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America AI-based Diabetic Eye Disease Screening System Sales Value (2021-2032) & (US$ Million) Figure 28. South America AI-based Diabetic Eye Disease Screening System Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa AI-based Diabetic Eye Disease Screening System Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa AI-based Diabetic Eye Disease Screening System Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • On-premise
  • Cloud-based
  • Hybrid Mode
Applications
  • General Hospitals
  • Ophthalmology Hospitals
  • Diabetes Specialty Hospitals
Companies covered
  • Remidio
  • Retmarker
  • VoxelCloud
  • Airdoc
  • Zhiyuan Huitu
  • IDx, LLC
  • Zhenhealth
  • Eyenuk
  • AEYE Health
  • Optomed

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global AI-based Diabetic Eye Disease Screening System Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global AI-based Diabetic Eye Disease Screening System Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 AI-based Diabetic Eye Disease Screening System Market Dynamics
  1. 2.1 AI-based Diabetic Eye Disease Screening System Industry Trends
  2. 2.2 AI-based Diabetic Eye Disease Screening System Industry Drivers
  3. 2.3 AI-based Diabetic Eye Disease Screening System Industry Opportunities and Challenges
  4. 2.4 AI-based Diabetic Eye Disease Screening System Industry Restraints
3 AI-based Diabetic Eye Disease Screening System Market by Company
  1. 3.1 Global AI-based Diabetic Eye Disease Screening System Company Revenue Ranking in 2025
  2. 3.2 Global AI-based Diabetic Eye Disease Screening System Revenue by Company (2021-2026)
  3. 3.3 Global AI-based Diabetic Eye Disease Screening System Company Ranking (2024-2026)
  4. 3.4 Global AI-based Diabetic Eye Disease Screening System Company Manufacturing Base and Headquarters
  5. 3.5 Global AI-based Diabetic Eye Disease Screening System Company Product Type and Application
  6. 3.6 Global AI-based Diabetic Eye Disease Screening System Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global AI-based Diabetic Eye Disease Screening System Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 AI-based Diabetic Eye Disease Screening System Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 AI-based Diabetic Eye Disease Screening System Market by Type
  1. 4.1 AI-based Diabetic Eye Disease Screening System Type Introduction
  2. 4.1.1 On-premise
  3. 4.1.2 Cloud-based
  4. 4.1.3 Hybrid Mode
  5. 4.2 Global AI-based Diabetic Eye Disease Screening System Sales Value by Type
  6. 4.2.1 Global AI-based Diabetic Eye Disease Screening System Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global AI-based Diabetic Eye Disease Screening System Sales Value by Type (2021-2032)
  8. 4.2.3 Global AI-based Diabetic Eye Disease Screening System Sales Value Share by Type (2021-2032)
5 AI-based Diabetic Eye Disease Screening System Market by Application
  1. 5.1 AI-based Diabetic Eye Disease Screening System Application Introduction
  2. 5.1.1 General Hospitals
  3. 5.1.2 Ophthalmology Hospitals
  4. 5.1.3 Diabetes Specialty Hospitals
  5. 5.2 Global AI-based Diabetic Eye Disease Screening System Sales Value by Application
  6. 5.2.1 Global AI-based Diabetic Eye Disease Screening System Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global AI-based Diabetic Eye Disease Screening System Sales Value by Application (2021-2032)
  8. 5.2.3 Global AI-based Diabetic Eye Disease Screening System Sales Value Share by Application (2021-2032)
6 AI-based Diabetic Eye Disease Screening System Regional Value Analysis
  1. 6.1 Global AI-based Diabetic Eye Disease Screening System Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global AI-based Diabetic Eye Disease Screening System Sales Value by Region (2021-2032)
  3. 6.2.1 Global AI-based Diabetic Eye Disease Screening System Sales Value by Region: 2021-2026
  4. 6.2.2 Global AI-based Diabetic Eye Disease Screening System Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America AI-based Diabetic Eye Disease Screening System Sales Value (2021-2032)
  7. 6.3.2 North America AI-based Diabetic Eye Disease Screening System Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe AI-based Diabetic Eye Disease Screening System Sales Value (2021-2032)
  10. 6.4.2 Europe AI-based Diabetic Eye Disease Screening System Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific AI-based Diabetic Eye Disease Screening System Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific AI-based Diabetic Eye Disease Screening System Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America AI-based Diabetic Eye Disease Screening System Sales Value (2021-2032)
  16. 6.6.2 South America AI-based Diabetic Eye Disease Screening System Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa AI-based Diabetic Eye Disease Screening System Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa AI-based Diabetic Eye Disease Screening System Sales Value Share by Country, 2025 VS 2032
7 AI-based Diabetic Eye Disease Screening System Country-level Value Analysis
  1. 7.1 Global AI-based Diabetic Eye Disease Screening System Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global AI-based Diabetic Eye Disease Screening System Sales Value by Country (2021-2032)
  3. 7.2.1 Global AI-based Diabetic Eye Disease Screening System Sales Value by Country (2021-2026)
  4. 7.2.2 Global AI-based Diabetic Eye Disease Screening System Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt AI-based Diabetic Eye Disease Screening System Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt AI-based Diabetic Eye Disease Screening System Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt AI-based Diabetic Eye Disease Screening System Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Remidio
  2. 8.1.1 Remidio Company Information
  3. 8.1.2 Remidio Business Overview
  4. 8.1.3 Remidio AI-based Diabetic Eye Disease Screening System Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Remidio AI-based Diabetic Eye Disease Screening System Product Portfolio
  6. 8.1.5 Remidio Recent Developments
  7. 8.2 Retmarker
  8. 8.2.1 Retmarker Company Information
  9. 8.2.2 Retmarker Business Overview
  10. 8.2.3 Retmarker AI-based Diabetic Eye Disease Screening System Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Retmarker AI-based Diabetic Eye Disease Screening System Product Portfolio
  12. 8.2.5 Retmarker Recent Developments
  13. 8.3 VoxelCloud
  14. 8.3.1 VoxelCloud Company Information
  15. 8.3.2 VoxelCloud Business Overview
  16. 8.3.3 VoxelCloud AI-based Diabetic Eye Disease Screening System Revenue and Gross Margin (2021-2026)
  17. 8.3.4 VoxelCloud AI-based Diabetic Eye Disease Screening System Product Portfolio
  18. 8.3.5 VoxelCloud Recent Developments
  19. 8.4 Airdoc
  20. 8.4.1 Airdoc Company Information
  21. 8.4.2 Airdoc Business Overview
  22. 8.4.3 Airdoc AI-based Diabetic Eye Disease Screening System Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Airdoc AI-based Diabetic Eye Disease Screening System Product Portfolio
  24. 8.4.5 Airdoc Recent Developments
  25. 8.5 Zhiyuan Huitu
  26. 8.5.1 Zhiyuan Huitu Company Information
  27. 8.5.2 Zhiyuan Huitu Business Overview
  28. 8.5.3 Zhiyuan Huitu AI-based Diabetic Eye Disease Screening System Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Zhiyuan Huitu AI-based Diabetic Eye Disease Screening System Product Portfolio
  30. 8.5.5 Zhiyuan Huitu Recent Developments
  31. 8.6 IDx, LLC
  32. 8.6.1 IDx, LLC Company Information
  33. 8.6.2 IDx, LLC Business Overview
  34. 8.6.3 IDx, LLC AI-based Diabetic Eye Disease Screening System Revenue and Gross Margin (2021-2026)
  35. 8.6.4 IDx, LLC AI-based Diabetic Eye Disease Screening System Product Portfolio
  36. 8.6.5 IDx, LLC Recent Developments
  37. 8.7 Zhenhealth
  38. 8.7.1 Zhenhealth Company Information
  39. 8.7.2 Zhenhealth Business Overview
  40. 8.7.3 Zhenhealth AI-based Diabetic Eye Disease Screening System Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Zhenhealth AI-based Diabetic Eye Disease Screening System Product Portfolio
  42. 8.7.5 Zhenhealth Recent Developments
  43. 8.8 Eyenuk
  44. 8.8.1 Eyenuk Company Information
  45. 8.8.2 Eyenuk Business Overview
  46. 8.8.3 Eyenuk AI-based Diabetic Eye Disease Screening System Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eyenuk AI-based Diabetic Eye Disease Screening System Product Portfolio
  48. 8.8.5 Eyenuk Recent Developments
  49. 8.9 AEYE Health
  50. 8.9.1 AEYE Health Company Information
  51. 8.9.2 AEYE Health Business Overview
  52. 8.9.3 AEYE Health AI-based Diabetic Eye Disease Screening System Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AEYE Health AI-based Diabetic Eye Disease Screening System Product Portfolio
  54. 8.9.5 AEYE Health Recent Developments
  55. 8.10 Optomed
  56. 8.10.1 Optomed Company Information
  57. 8.10.2 Optomed Business Overview
  58. 8.10.3 Optomed AI-based Diabetic Eye Disease Screening System Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Optomed AI-based Diabetic Eye Disease Screening System Product Portfolio
  60. 8.10.5 Optomed Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst